GlassScriptPhysician profile
Ronald C Colman
NPI 1871579417
$4,796.18
in general payments reported to CMS, 2019-2025
29 companies · $541 in 2025
The $541 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $475 · 2021: $860 · 2022: $1,061 · 2023: $365 · 2024: $354 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243 · Education: $16.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.09 |
| Education | $16.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.07 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Scientific Affairs, LLC | $434.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.40 | 2020-2023 | Entyvio |
| Janssen Biotech, INC. | $273.88 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.77 | 2019-2022 | |
| Genzyme Corporation | $263.90 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $177.23 | 2019-2023 | Rebyota |
| Alexion Pharmaceuticals, INC. | $166.54 | 2022-2024 | Ultomiris |
| Amgen INC. | $134.54 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $125.22 | 2025 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Kyowa Kirin, INC. | $120.20 | 2025 | |
| Novo Nordisk INC | $114.18 | 2025 | |
| Merck Sharp & Dohme LLC | $81.22 | 2021-2023 | Dificid |
| Otsuka America Pharmaceutical, INC. | $60.80 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $54.17 | 2019-2021 | |
| Vifor Pharma, INC. | $40.05 | 2019 | |
| Dynavax Technologies Corporation | $26.03 | 2025 | Heplisav-B |
| Allergan, INC. | $23.63 | 2019-2020 | |
| Horizon Therapeutics Plc | $22.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.49 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.90 | 2020 | |
| Ardelyx, INC. | $16.69 | 2023 | Ibsrela |
| Celltrion USA INC. | $15.64 | 2025 | Vegzelma |
| Qol Medical, LLC | $15.01 | 2022 | |
| Shionogi INC | $14.94 | 2019 | |
| Redhill Biopharma INC. | $14.87 | 2021 | |
| Celgene Corporation | $14.83 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Colman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.